Objetivo: Avaliar se a radioiodoterapia com 131I-metaiodobenzilguanidina (131I-mIBG) aumenta sobrevida de pacientes diagnóstico neuroblastoma, mIBG-ávido, refratários ao tratamento ou alto risco para recidiva, independentemente do estadiamento da doença. Métodos: Revisão sistemática literatura. Consultadas as bases Medline (PUBMED), EMBASE e Cochrane Library, sendo incluídos estudos disponíveis...

131I-TM-601 is a 36-amino acid peptide, called chlorotoxin (TM-601), derived from scorpion venom labeled with I-131. TM-601 binds a receptor on the surface of tumor cells, and not on normal cells. A single dose of 131I-TM-601 administered intracranially to human xenografted mouse models of glioma has been shown to extend survival up to 269% in multiple studies. 131I-TM-601 is in a multi-center ...

131I-TM-601 is a 36-amino acid peptide, called chlorotoxin (TM-601), derived from scorpion venom labeled with I-131. TM-601 binds a receptor on the surface of tumor cells, and not on normal cells. A single dose of 131I-TM-601 administered intracranially to human xenografted mouse models of glioma has been shown to extend survival up to 269% in multiple studies. 131I-TM-601 is in a multi-center ...

Based on the positron emission tomography (PET) computed (CT) image segmentation algorithm, this article explores application of PET/CT in recurrence and metastasis thyroid cancer after differentiated (DTC). In study, 132 patients with DTC combined 131I treatment underwent whole-body imaging scan (131I-WBS), serum thyroglobulin (Tg) level was measured at same time. Among 54 Tg-positive patients...

objective: the current study aimed to determine the efficacy of radioiodine-131 (131i) ablation therapy with thyroid hormone replacement one day before 131i administration in patients with well-differentiated thyroid cancer (dtc). methods: this retrospective study included 29 patients who underwent 131i therapies twice for dtc during 6-12 months.  since all the patients obviously had residual l...

Objective: The current study aimed to determine the efficacy of radioiodine-131 (131I) ablation therapy with thyroid hormone replacement one day before 131I administration in patients with well-differentiated thyroid cancer (DTC). Methods: This retrospective study included 29 patients who underwent 131I therapies twice for DTC during 6-12 months.  Since all the patients obviously had residual l...

Herein, folic acid (FA) conjugated Poly(d,l-lactide-co-glycolide) (PLGA)-lipid composites (FA-PL) were developed as nanocarriers for the targeted delivery of insoluble anti-cancer drug paclitaxel (PTX), resulting FA-PLP nanoparticles. Furthermore, 131I, as a radioactive tracer, was used to label FA-PLP nanoparticles (FA-PLP-131I) to evaluate their cell uptake activity, in vivo blood circulation...

Objective: The aim of this study was to explore the clinical characteristics of renal metastatic cancer, the methods for its detection by radioiodine (131I), and the response to 131I treatment in fourteen patients with renal metastases from differentiated thyroid carcinoma (DTC). Subjects and methods: DTC patients (n = 2,955) that received treatment with 131I were retrospectively analyzed. Scan...

The role of thallium-201 (201TI) scintigraphy in the follow-up evaluation of differentiated thyroid carcinoma (DTC) is controversial. Desirable characteristics of 201TI scintigraphy including the potential for no thyroid hormone withdrawal, immediate imaging postinjection, and low radiation burden relative to iodine-131 (131I) suggests it is logistically superior to 131I scintigraphy. Fifty-two...